Other live channels you can watch
Welcome and Opening of the Biotech Atelier
Advanced therapy medicinal products (ATMPs)
Digital Health and Artificial Intelligence
Real-World Evidence (RWE) and HTA
Personalized Medicine: Recent Developments
Personalized Medicine: Biomarkers
Human Capital in “Corona Times” and beyond
The Life Science Funding in “Corona Times” and beyond
Biotechnology Innovation and Investment – Before, Now and Then
Innovations in the COVID-19 Era
Artificial Intelligence in the COVID-19 Era
Personalized Medicine: Biobanking and Population Genetics
Future of clinical trials, AI and data
Personalization, Pharmacogenetics and Pharmacogenomics
Innovation in Medicine – ATMPs
How Germany managed the coronavirus crisis
Regulatory Challenges in the COVID Era
Medical Cannabis – the Wonder Substance
Hospital Exemption for ATMPs
Medical Devices in the Digital Health Era
COVID-19: the New Reality in Bulgaria and Worldwide
COVID-19 Diagnostic and Therapy, the Bulgarian Perspective
COVID-19 Diagnostics: Hear the Experts
Water and Biotechnologies
Plant Biotechnology: Beyond
Healthcare and Pharma Dynamics, 2020
Precision Medicine’s Potential and Current Gaps
ATMPs, patient’s perspective
ATMPs, Leveraging the Digital Supply Chain
IBM Solutions in Healthcare
The Supercomputers – modern accelerators of innovation in healthcare
Beyond healthcare system towards a health-tech ecosystem
3D Bioprinting? (CTI Biotech)
Big Data and AI in Digital Health
BDADH – GATE Institute – Research areas and application themes
BDADH – Session 2 opening
BDADH – Session 1 opening
BDADH – Detecting and characterizing complex variation in the human genome sequence that can affect brain function
BDADH – Non-invasive biomarker detection, identification, and computational modeling for neonatal health
BDADH – Leveraging AI and RWE Big Data to Develop Novel Multi-omic AI Diagnostic Test for Immuno-Oncology Therapy in Lung Cancer
BDADH – Session 2 opening
BDADH – Clinical aspects of dementia management and follow-up in Bulgaria and opportunities for digitalisation
BDADH – Digital twin modelling of patients with cognitive disorders
Healthtech and Biotech startup track
PBB – The future of plant agriculture
PBB – Will computational biology push the next breakthrough in plant biotechnology and breeding?
FCTAID – Welcome and opening
FCTAID – Setting the scene: Future of clinical trials – what it would be?
FCTAID – Clinical Research Landscape in Bulgaria – From Status Quo toward Status GO!
FCTAID – Clinical Trials market & Financial impact – Global overview
FCTAID – Scientific evidence based ethical assessment. Future objectives of national ethics committee.
FCTAID – The lack of data as an obstacle to the clinical trials development in CEE
FCTAID – Patient-centric software powering decentralised trials
FCTAID – Research transparency, public involvement and proportionality of ethical review
FCTAID – Activities of the Ethics Committee for Clinical Trials in Bulgaria to meet the challenges of the new regulatory requirements in the EU and to improve the environment for conducting clinical trials in Bulgaria
FCTAID – Decentralised clinical trials: moving from nicety to necessity
FCTAID – High level overview of several digital innovations and technologies that help advance healthcare research and clinical care
FCTAID – NIHR Clinical Research Network: the delivery arm of the NHS
FCTAID – How to embed research in a national health service
FCTAID – Clinical Trials in Bulgaria – Key Challenges
FCTAID – Sleep disorders and clinical trials: new challenges and perspectives
FCTAID – At a time of a global pandemic we recognize more than ever the need for clinical research- key note on the importance, benefits and socio-economic impact of clinical trials
FCTAID – Romanian clinical trials market – huge potential suffocated by lack of vision
FCTAID – The importance of clinical research in saving patient’s life – academy point of view
FCTAID – Improved adverse event/medical error reporting
FCTAID – Conclusions and closure
FCTAID – Using AI to generate Real World Evidence (RWE)
PPP – Welcome and Opening
PPP – Personalized Medicine – the New Reality in Medical School?
PPP – Moving from disease treatment to disease prevention – personalization is the key
PPP – Implementation of Pharmacogenetic testing: what are the priorities?
PPP – Pharmacogenetics in oncology clinical practice
PPP – Progressing a data driven healthcare system
PPP – Donor-derived cell-free DNA testing in organ transplantation: a value proposition
PPP – Enhancing Precision Medicine and Pharmacogenetics through Clinical Mass Spectrometry Platform
PPP – Rational Cancer Therapy
PPP – Closing discussion and remarks
ATMPs – EU ATMP development landscape and outlook
ATMPs – ATMP update and Regulatory Strategy
ATMPs – Nonclinical Challenges and Cases with ATMPs
ATMPs – CMC Challenges and case studies with ATMPs
ATMPs – The ATMP post approval path – patient and market access
ATMPs – Riding the clinical trial rollercoaster – a patient’s perspective
FCTAID – Patient First: changing the clinical trials paradigm
IRI – Research infrastructures: Why do we need them?
IRI – Covid – what can infrastructures do going forward
IRI – Infrastructures Role in developing Personalized Health
Potable water and biotechnologies
Topic for the near future: Water microbiome
Wastewater and Biotechnologies
The future of the water sector: Matching needs and technologies
Potable Water and Biotechnologies
Wastewater and Biotechnologies
Lunch and networking time
The Future of the Water Sector – Matching Needs and Technologies
Genomics and data to support personalised medicine (incl. registers/biobanks, biomarkers assessment)
Discussion panel with Q&A from the audience
Adoption of personalised medicine (incl. patient centricity, health technology assessment, regulations)
Discussion panel with Q&A from the audience
Personalised medicine – what the future brings?
Discussion panel with Q&A from the audience
Welcome and Opening of the Biotech Atelier
Advanced therapy medicinal products (ATMPs)
Digital Health and Artificial Intelligence
Real-World Evidence (RWE) and HTA
Personalized Medicine: Recent Developments
Personalized Medicine: Biomarkers
Human Capital in “Corona Times” and beyond
The Life Science Funding in “Corona Times” and beyond
Biotechnology Innovation and Investment – Before, Now and Then
Innovations in the COVID-19 Era
Artificial Intelligence in the COVID-19 Era
Personalized Medicine: Biobanking and Population Genetics
Future of clinical trials, AI and data
Personalization, Pharmacogenetics and Pharmacogenomics
Innovation in Medicine – ATMPs
How Germany managed the coronavirus crisis
Regulatory Challenges in the COVID Era
Medical Cannabis – the Wonder Substance
Hospital Exemption for ATMPs
Medical Devices in the Digital Health Era
COVID-19: the New Reality in Bulgaria and Worldwide
COVID-19 Diagnostic and Therapy, the Bulgarian Perspective
COVID-19 Diagnostics: Hear the Experts
Water and Biotechnologies
Plant Biotechnology: Beyond
Healthcare and Pharma Dynamics, 2020
Precision Medicine’s Potential and Current Gaps
ATMPs, patient’s perspective
ATMPs, Leveraging the Digital Supply Chain
IBM Solutions in Healthcare
The Supercomputers – modern accelerators of innovation in healthcare
Beyond healthcare system towards a health-tech ecosystem
3D Bioprinting? (CTI Biotech)
Big Data and AI in Digital Health
BDADH – GATE Institute – Research areas and application themes
BDADH – Session 2 opening
BDADH – Session 1 opening
BDADH – Detecting and characterizing complex variation in the human genome sequence that can affect brain function
BDADH – Non-invasive biomarker detection, identification, and computational modeling for neonatal health
BDADH – Leveraging AI and RWE Big Data to Develop Novel Multi-omic AI Diagnostic Test for Immuno-Oncology Therapy in Lung Cancer
BDADH – Session 2 opening
BDADH – Clinical aspects of dementia management and follow-up in Bulgaria and opportunities for digitalisation
BDADH – Digital twin modelling of patients with cognitive disorders
Healthtech and Biotech startup track
PBB – The future of plant agriculture
PBB – Will computational biology push the next breakthrough in plant biotechnology and breeding?
FCTAID – Welcome and opening
FCTAID – Setting the scene: Future of clinical trials – what it would be?
FCTAID – Clinical Research Landscape in Bulgaria – From Status Quo toward Status GO!
FCTAID – Clinical Trials market & Financial impact – Global overview
FCTAID – Scientific evidence based ethical assessment. Future objectives of national ethics committee.
FCTAID – The lack of data as an obstacle to the clinical trials development in CEE
FCTAID – Patient-centric software powering decentralised trials
FCTAID – Research transparency, public involvement and proportionality of ethical review
FCTAID – Activities of the Ethics Committee for Clinical Trials in Bulgaria to meet the challenges of the new regulatory requirements in the EU and to improve the environment for conducting clinical trials in Bulgaria
FCTAID – Decentralised clinical trials: moving from nicety to necessity
FCTAID – High level overview of several digital innovations and technologies that help advance healthcare research and clinical care
FCTAID – NIHR Clinical Research Network: the delivery arm of the NHS
FCTAID – How to embed research in a national health service
FCTAID – Clinical Trials in Bulgaria – Key Challenges
FCTAID – Sleep disorders and clinical trials: new challenges and perspectives
FCTAID – At a time of a global pandemic we recognize more than ever the need for clinical research- key note on the importance, benefits and socio-economic impact of clinical trials
FCTAID – Romanian clinical trials market – huge potential suffocated by lack of vision
FCTAID – The importance of clinical research in saving patient’s life – academy point of view
FCTAID – Improved adverse event/medical error reporting
FCTAID – Conclusions and closure
FCTAID – Using AI to generate Real World Evidence (RWE)
PPP – Welcome and Opening
PPP – Personalized Medicine – the New Reality in Medical School?
PPP – Moving from disease treatment to disease prevention – personalization is the key
PPP – Implementation of Pharmacogenetic testing: what are the priorities?
PPP – Pharmacogenetics in oncology clinical practice
PPP – Progressing a data driven healthcare system
PPP – Donor-derived cell-free DNA testing in organ transplantation: a value proposition
PPP – Enhancing Precision Medicine and Pharmacogenetics through Clinical Mass Spectrometry Platform
PPP – Rational Cancer Therapy
PPP – Closing discussion and remarks
ATMPs – EU ATMP development landscape and outlook
ATMPs – ATMP update and Regulatory Strategy
ATMPs – Nonclinical Challenges and Cases with ATMPs
ATMPs – CMC Challenges and case studies with ATMPs
ATMPs – The ATMP post approval path – patient and market access
ATMPs – Riding the clinical trial rollercoaster – a patient’s perspective
FCTAID – Patient First: changing the clinical trials paradigm
IRI – Research infrastructures: Why do we need them?
IRI – Covid – what can infrastructures do going forward
IRI – Infrastructures Role in developing Personalized Health
Potable water and biotechnologies
Topic for the near future: Water microbiome
Wastewater and Biotechnologies
The future of the water sector: Matching needs and technologies
Potable Water and Biotechnologies
Wastewater and Biotechnologies
Lunch and networking time
The Future of the Water Sector – Matching Needs and Technologies
Genomics and data to support personalised medicine (incl. registers/biobanks, biomarkers assessment)
Discussion panel with Q&A from the audience
Adoption of personalised medicine (incl. patient centricity, health technology assessment, regulations)
Discussion panel with Q&A from the audience
Personalised medicine – what the future brings?
Discussion panel with Q&A from the audience
Skip to content
